PATIENT ACCESS 340B PHARMACY
SB2385 creates the Patient Access to Pharmacy Protection Act, a new Illinois law aimed at protecting the federal 340B drug discount program and the use of contract pharmacies. The bill prohibits any person, including pharmaceutical manufacturers, from interfering with the acquisition or delivery of 340B drugs to covered entities or their contract pharmacies, unless federal law prohibits the transaction. It also bars manufacturers from restricting how many, where, or what type of contract pharmacies a covered entity may use.
The bill further prevents manufacturers from requiring 340B entities or contract pharmacies to provide ingredient-cost or pricing data, impose non-government inventory management requirements, or submit information not required by state or federal law as a condition of receiving 340B drugs. It establishes enforcement authority in the Department of Financial and Professional Regulation and allows the Department, the Attorney General, State’s Attorneys, and covered entities or contract pharmacies to seek injunctive relief, damages, civil penalties of up to $10,000 per violation, and attorney’s fees. The Act would take effect immediately and includes preemption and severability provisions.
If enacted, SB2385 would add a new state regulatory framework governing how 340B drugs are distributed and how manufacturers may interact with Illinois 340B covered entities and contract pharmacies. It would create enforceable state-law protections for hospitals, clinics, and pharmacies participating in the 340B program, while limiting manufacturers’ ability to impose contractual, reporting, audit, or inventory-related conditions beyond what state or federal law requires. The bill would also authorize state enforcement actions and private civil suits, potentially increasing litigation exposure for pharmaceutical manufacturers and other persons that attempt to restrict 340B distribution.
The bill’s findings and structure indicate strong support for expanding and protecting access to discounted medications, especially for rural and medically underserved communities. The overall tone is pro-access and pro-provider, with the General Assembly framing the measure as a health, safety, and welfare issue. No committee transcript or vote data is available, so there is no recorded formal debate or roll-call sentiment in the provided materials.
The main point of contention is likely to be the bill’s restriction on pharmaceutical manufacturers’ ability to control 340B distribution, contract pharmacy arrangements, and data collection. Supporters would view these limits as necessary to preserve patient access and prevent manufacturers from narrowing the program, while opponents may argue the bill interferes with manufacturer oversight, inventory integrity, pricing transparency, and compliance monitoring. The bill also raises potential legal tension over state authority versus federal 340B rules, though it includes preemption language and an exception for federally required limited distribution drugs.